IP Library Granted Patent US 9,758,763
Granted Patent B2
US 9,758,763 · App. 14/288,117 · Granted Sep 12, 2017

Methods and compositions for somatic cell proliferation and viability

Inventors: Irina M. Conboy (El Sobrante, CA); Michael J. Conboy (El Sobrante, CA); Hanadie Yousef (Berkeley, CA); David V. Schaffer (Danville, CA)
Assignee: The Regents of the University of California
C12N5/0619C12N5/0659C12N2501/91C12N2502/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,758,763
App. No.
14/288,117
Granted
Sep 12, 2017
Kind
B2
Abstract

Methods and compositions for somatic cell proliferation as well as increasing viability of somatic cells are provided. The compositions include heparin binding protein isolated from a medium conditioned by growth of pluripotent stem cells, such as, human embryonic stem cells, human embryonic carcinoma cells. The methods include contacting a somatic cell with a heparin binding protein composition for a sufficient period of time to provide for enhanced proliferation and/or viability of the somatic cell as compared to the absence of the heparin binding protein composition.

Claims (16)

1. A method for enhancing proliferation of a muscle cell, the method comprising:

isolating all heparin binding proteins from a medium conditioned by growth of human embryonic stem cells or human embryonic carcinoma cells, wherein the medium is essentially free of human embryonic stem cells or human embryonic carcinoma cells and wherein the isolating comprises contacting the medium with a solid support conjugated to heparin and eluting the heparin binding proteins bound to the solid support;

contacting a muscle cell with a composition comprising all of the heparin binding proteins isolated from the medium conditioned by growth of human embryonic stem cells or human embryonic carcinoma cells,

wherein the contacting is for a period of time sufficient to provide for enhanced proliferation of the muscle cell compared to the absence of the heparin binding proteins.

2. The method of claim 1 , wherein the muscle cell is cell of an aged subject.

3. The method of claim 1 , wherein the muscle cell is an injured cell.

4. The method of claim 3 , wherein the injury is caused by a disease.

5. The method of claim 1 , wherein the muscle cell is a diseased cell.

6. The method of claim 1 , wherein the muscle cell is a skeletal muscle cell.

7. The method of claim 6 , wherein the skeletal muscle cell is a myoblast.

8. The method of claim 1 , wherein the muscle cell is an activated satellite cell.

9. The method of claim 1 , wherein the heparin binding proteins are isolated from a medium conditioned by growth of human embryonic stem cells.

10. The method of claim 2 , wherein the muscle cell is a skeletal muscle cell.

11. The method of claim 10 , wherein the skeletal muscle cell is a myoblast.

12. The method of claim 2 , wherein the muscle cell is an activated satellite cell.

13. The method of claim 3 , wherein the muscle cell is a skeletal muscle cell.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 1, 2014
From: UNIVERSITY OF CALIFORNIA BERKELEY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034500/0835 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2014
From: CONBOY, IRINA M.; CONBOY, MICHAEL J.; YOUSEF, HANADIE; SCHAFFER, DAVID V.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 034167/0885 →
Continuity (2)
Provisional Application 61828543 · May 29, 2013
Related Publication 20140356947A1 · Dec 4, 2014